Skip to main content

Table 2 In vivo outcome of AS/SP and AL

From: A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan

 

Prevalence n (%)

 

AS/SP

AL

ETF

1 (1.3)

0 (0)

LCF

3 (3.9)

5 (6.3)

LPF

8 (10.4)

3 (3.8)

ACPR

65 (84.4)

72 (90)

Total analysed

77 (96.3)

80 (100)

WITH

3 (3.7)

0 (0)

TOTAL

80

80

  1. ETF; early treatment failure; LCF: late clinical failure; LPF: late parasitological failure; ACPR: adequate clinical and parasitological response; WITH: withdrawal; as analysed by the WHO worksheet.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us